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Background: Delirium is a serious and distressing neuropsychiatric 
condition, which is prevalent across all palliative care settings. 
Hypoactive delirium is particularly common, but difficult to recognize, 
partly due to overlapping symptoms with depression and dementia.  
Delirium screening tools can lead to earlier identification and hence 
better management of patients. The 4AT (4 ‘A’s Test) is a brief tool for 
delirium detection, designed for use in clinical practice. It has been 
validated in 17 studies in over 3,700 patients. The test is currently 
used in specialist palliative care units, but has not been validated in 
this setting.  The aim of the study is to determine the diagnostic 
accuracy of the 4AT for delirium detection against a reference 
standard, in hospice inpatients. 
Methods: 240 participants will be recruited from the inpatient units of 
two hospices in Scotland. If a patient lacks capacity to consent, 
agreement will be sought from a legal proxy.  Each participant will 
complete the 4AT and a reference standard assessment based on the 
diagnostic delirium criteria in the fifth edition of the Diagnostic and 
Statistical Manual of Mental  Disorders (DSM-5). This will be 
supplemented by tests of cognition and  attention, including reverse 
days of the week, counting down from 20 to 1, Vigilance 'A', the 
Observational Scale for Level of Arousal, the modified Richmond 
Agitation Sedation Scale and the Delirium Rating Scale-Revised-98. 
The assessments will be conducted in a randomized order by two 
independent clinicians, who will be blinded to the results until both 
are complete. Primary outcomes will be the sensitivity and specificity 
of the 4AT in detecting delirium. 
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Plain language summary
Delirium is a serious and distressing condition, which commonly 
affects people with terminal illness. Approximately a third of 
patients will have delirium on admission to hospices. Delirium 
usually develops over hours to days. It can cause confusion, and 
problems with memory, concentration, perception (may develop 
hallucinations) and altered consciousness (people can become 
agitated or drowsy and withdrawn). It is important to diag-
nose delirium early, as it increases the person’s chance of recov-
ery. When a person has only hours or days to live, their delirium 
is less likely reversible, but early detection is still beneficial, 
as it helps healthcare professionals decide how they can best 
support the person and their family.
The 4’A’s test or 4AT is a short, easy to administer bedside test, 
used by healthcare professionals to determine if patients may 
have delirium. Research has shown the 4AT to be an effective 
test in hospital patients. It is currently used in hospices, but 
research is needed to review its use in this setting. This article 
describes the proposed study to examine the effectiveness of 
the 4AT in detecting delirium in terminally ill hospice patients.
Patients admitted to two hospices in Scotland will be invited 
to take part in the study. Those participating in the study will 
undergo two assessments - the 4AT and another more detailed 
delirium assessment.
This study will provide evidence about the accuracy of the 4AT 
in detecting delirium in terminally ill hospice patients. If the 
study shows the 4AT to be effective, it may be more readily 
used in routine practice, than other more complex and lengthy 
delirium tests. If delirium is detected earlier, it may lead to 
better care for these patients and their families.
Abbreviations
DSM-5         Diagnostic and Statistical Manual of Mental Disorders, 
5th edition
DSM-IV       Diagnostic and Statistical Manual of Mental 
Disorders, 4th edition
DSM-III      Diagnostic and Statistical Manual of Mental 
Disorders, 3rd edition, Revised
CAM            Confusion Assessment Method
bCAM         Brief Confusion Assessment Method
4AT             4 ‘A’s test
SQiD           Single Question in Delirium
NuDESC     Nursing Delirium Screening Scale
DOS            Delirium Observation Scale
DRS            Delirium Rating Scale
DRS-R-98   Delirium Rating Scale Revised 98
MDAS         Memorial Delirium Assessment Scale
AMT-4        Abbreviated Mental Test -4
CCC            Concordance Correlation Coefficient
ACCORD     Academic and Clinical Central Office for Research 
and Development
Background
Delirium is a serious and distressing neuropsychiatric condition, 
characterized by an acute disturbance in attention, awareness 
and cognition. Delirium severity may fluctuate throughout the 
day, and be associated with disturbances in the sleep-wake cycle. 
Cognitive changes may impact memory, orientation, language, 
visuospatial ability and perception1. Delirium can be highly 
distressing for patients and their families and is associated with 
poor outcomes2–6.
Delirium is extremely common across all palliative care 
settings7,8. A recent systematic review estimated the median 
(range) point prevalence of delirium on admission to palliative 
care inpatient settings as 32% (6.6%–73%) and period preva-
lence prior to death as 75% (58%–88%)7. Hypoactive delirium is 
more common than other subtypes in palliative care9–11 but may 
be less noticeable and go under-recognised due to overlapping 
symptoms with depression, dementia and fatigue11–13.
International guidance recommends routine assessment for 
risk factors of delirium on admission to hospital and other care 
settings, and subsequently if there are any fluctuations or changes 
in behaviour or cognition14–18. Delirium assessment tools are rec-
ommended and may lead to earlier detection. Improved detec-
tion may lead to better management, including investigation 
and treatment of the underlying cause and/or better symptom 
control, resulting in more favourable outcomes for both 
patients and their families.
Delirium tools are available for different purposes19:
•    for delirium detection at first presentation, and at other times 
when delirium is first suspected: the Confusion Assessment 
Method (CAM)20, shorter versions, including the brief Confu-
sion Assessment Method (bCAM)21, the 4 ‘A’s test (4AT)22 and 
informant screening tools, such as the Single Question in 
Delirium (SQiD)23.
•    for monitoring of new onset delirium in inpatients, on a regu-
lar basis, daily or more frequently: the Nursing Delirium 
Screening Scale (NuDESC)24 and Delirium Observation Scale 
(DOS)25.
•    as research assessments: The Delirium Rating Scale (DRS) 
and the Delirium Rating Scale Revised-98 (DRS-R-98)26.
Table 1 shows examples of validation studies in palliative care and 
oncology populations.
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Table 1. Validation studies of Delirium assessment tools used in palliative care and oncology populations27–29.
Assessment 
tool










to DSM-IIIR and 
DSM-IV delirium 
diagnosis
Sensitivity 0.71, Specificity 0.94 
(cut-off score 13)
The MDAS is a brief, reliable tool 
for assessing delirium severity 
among medical inpatients. It 
may also be useful in delirium 
diagnosis.
51 Hospitalised 




to Delirium Rating 
Scale (DRS) and 
Clinician’s Global 
Rating of Delirium 
Severity 
There was high correlation 
between MDAS scores and 
the alternative measures of 
delirium: DRS (r = 0.88,  
p < 0.0001) and Clinician’s 
Global Rating of Delirium 







MDAS compared to 
DSM-IV diagnosis
Sensitivity 0.97, Specificity 0.95 
(cutoff score 7)
The MDAS is a valid and reliable 
tool for delirium diagnosis and 
severity monitoring. 
Proration of MDAS total scores was 
required in approximately a fifth 
of delirious patients. This may limit 
the use of MDAS in research, but 
be useful in clinical practice.
77 palliative care 
unit inpatients 
(O’Sullivan, 2015)32
MDAS compared to 





There was substantial overall 
agreement in the severity scores 





Pilot study with 32 
patients, followed 
by main study with 
52 palliative care 
unit inpatients 
(Ryan, 2009)33
CAM compared to 
DSM-IV diagnosis
Pilot study: 
Sensitivity 0.5, specificity 1.0. 
 
Main study (assessors received 
more training of CAM than in 
pilot study): 
Sensitivity 0.88, Specificity 1.0
The CAM is a valid screening tool 
in palliative care inpatients, but 
accuracy depends on assessors’ 







Sensitivity 0.4, Specificity 0.92. Primary focus of this study was the 
SQiD. 
The CAM performed poorly, likely 
because the assessors had limited 










R-98 and clinical 
judgement
Incidence of delirium was 29% 
based on clinical judgement 
alone, but increased to 43% 
when validated assessment 
tools (CAM and/or DRS-R-98) 
were used.
The study supports the short CAM 
as an appropriate screening tool. 
The DRS-R-98 is limited as a 
screening tool by its complexity 
and time taken to administer.
36 palliative care 
unit inpatients or 
other inpatients 
reviewed by 
palliative care team 
(Wilson, 2019)34
Brief CAM 
compared to DSM-5 
diagnosis
Sensitivity 0.80, Specificity 0.87 The brief CAM was found to have 
good sensitivity and specificity in 
veteran palliative care inpatients, 
but further validation studies with 












Sensitivity 0.86, Specificity 0.87 The Nu-DESC, a brief, easy to use 
tool, demonstrated high diagnostic 
accuracy in oncology inpatients, 
but further studies with larger 
sample size are required.





There was positive correlation 
between the 24 hour maximum 
and mean Nu-DESC scores and 
the MDAS (r=0.41, p=0.006, and 
r=0.40, p=0.008 respectively); 
but lower or insignificant 
correlation when Nu-DESC 
scores using items 2-4 were 
used.
The Nu-DESC may be useful 
to monitor delirium severity in 
palliative care inpatients.
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Assessment 
tool





48 palliative care 
unit inpatients 
(Detoyer, 2014)36
DOS compared to 
CAM
Sensitivity 0.82, Specificity 0.96 The DOS can be used as a 
screening tool in ‘verbally active’ 
palliative care inpatients. The tool 
is quick and easy to score. Further 
validation studies are required.
78 assessments 
of home hospice 
patients 
( Jorgensen, 2016)37
DOS compared to 
DRS-R-98
Sensitivity 0.97, Specificity 0.89 The DOS is a useful observational 
screening tool in home hospice 
patients. It is quick to learn and 
cognitive testing is not required. 





DOS compared to 
DRS-R-98
Sensitivity >0.99, Specificity >0.99 The DOS is a brief, accurate 













SQiD: Sensitivity 0.8, Specificity 
0.71, 
CAM: Sensitivity 0.4, Specificity 
0.92
The SQiD is a quick and easy to use 
tool, which can be incorporated 
into the admission process. 
If the SQiD scores positive, this 
could trigger a more detailed 
assessment for delirium. 
The CAM performed poorly in this 
study, likely because the assessors 
had limited training in its use.








Used as reference standard delirium assessments in research studies11,30,32,37,38
The DRS-R-98, a clinician-rated 16-item scale with 3 diagnos-
tic and 13 severity scales, is able to distinguish reliably from 
depression and dementia26. Use in clinical practice is limited 
because of training required prior to use and time taken to admin-
ister (at least 20–30 minutes with the patient, plus additional time 
to gather informant history and review case notes)11,27.
The Memorial Delirium Assessment Scale (MDAS), a 10-item 
scale, used for delirium detection and severity monitoring, takes 
approximately 10 minutes with the patient, plus additional 
time to gather informant history30. It has a simpler format and is 
easier to rate than the DRS-R-98, but still requires moder-
ate training to administer27. A study in a palliative care inpatient 
unit demonstrated 97% sensitivity and 95% specificity (cutoff 
score = 7)31.
The CAM and its shorter variants are quicker to administer than 
either the MDAS or DRS-R-98 (approximately 5–10 minutes), 
but still require moderate training prior to use, as well as addi-
tional cognitive testing27. Aspects requiring subjective judgement 
by the assessor can be more complex and time-consuming to 
rate, plus there is limited advice for scoring non-verbalizing 
patients39. This may account for high levels of sensitivity and 
specificity in some studies33,34, but lower results when scored by 
those less experienced23,33.
The informant tool, the Single Question in Delirium (SQiD), 
which asks ‘Do you feel that (patient’s name) has been more 
confused lately?’, has been validated in oncology patients 
(80% sensitivity and 71% specificity), but not in palliative care 
patients23. Use of the SQiD is limited when an informant is 
unavailable.
The 4‘A’s Test (4AT) is a short bedside test for detecting delir-
ium, for use in clinical practice22. It takes a few minutes to 
complete and incorporates 4 items: (1.) An observational meas-
ure of alertness, (2.) The Abbreviated Mental Test-4 (AMT4), 
(3.) The Months of the Year Backwards test, and (4.) Evidence 
of significant change or fluctuation in alertness, cognition or 
other mental function arising over the last 2 weeks and still 
evident in the last 24 hours. The first 3 items are assessed 
at the patient’s bedside. The last item is derived directly by 
the assessor or from informant history (i.e. taken from case 
notes, clinical staff or a relative or carer). The 4AT can be 
used by any healthcare professional, either at first contact or 
when delirium is suspected. It is one of the most frequently 
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validated delirium tools in the literature. A recent system-
atic review and meta-analysis of 17 studies involving 3702 
older adults in medicine, surgery, emergency and care home 
settings, demonstrated a pooled sensitivity of 88% and pooled 
specificity of 88%40. The 4AT’s advantages over other tools 
are that no special training is required prior to use, and it is 
quick and easy to administer. Furthermore, all patients can be 
assessed, including those unable to communicate (patients with 
severe drowsiness or agitation.)
The 4AT is recommended for identifying patients with 
delirium14, and is currently used in palliative care settings41–43, 
but has not been validated for delirium screening in a terminally 
ill population.
Study objective
The study objective is to determine whether the 4AT is a valid 
tool for delirium detection in specialist palliative care settings. 
The diagnostic accuracy of the 4AT will be compared against 
a reference standard delirium assessment, based on the diagnos-
tic criteria of the fifth edition of the Diagnostic and Statistical 
Manual of Mental Disorders (DSM-5) (Table 2)1.
Methods
Study overview
In developing this protocol, we drew on the study design and 
procedures of a previous 4AT validation study conducted in 
emergency departments and acute medical wards39. This study 
is a prospective diagnostic accuracy study of the 4AT in a 
representative sample of hospice inpatients. Each participant 
will independently complete the 4AT and the reference standard 
delirium assessment based on DSM-5 criteria. Study procedures 
are described in Figure 1. 
Setting
The study will take place at two hospices in Scotland. 
The hospices have 17 and 24 inpatient beds, respectively, and 
admitted a combined total of 700 patients in 2019. Patients with 
advanced progressive or incurable disease are admitted for 
complex end of life care, or because they have uncontrolled 
pain and/or other complex physical or psychological issues, that 
cannot be managed in other care settings.
Participants and sample size
Participants admitted acutely to the hospices will be included 
if they are aged 18 years or over. Patients will be excluded if 
they are comatosed, unable to communicate in English, are 
severely dysphasic or have a combined severe hearing and vis-
ual impairment, which would limit participation in the study’s 
tests. Patients will also be excluded if there is a high level of 
patient and family distress, as judged by the clinical team, or the 
patient has an acute life-threatening illness requiring time- 
critical intervention (e.g. suspected spinal cord compression).
A recent meta-analysis of 17 studies on the diagnostic accuracy 
of the 4AT in a variety of clinical settings, reported a pooled 
sensitivity of 0.88 (95% CI 0.80-0.93) and a pooled specificity 
of 0.88 (95% CI 0.82-0.92)40. In line with guidance described 
by Flahault et al. (2005)44 which suggests a sample size of 176, 
given a sensitivity/specificity of 0.85, and a minimal acceptable 
lower confidence level of 0.75, we plan to recruit 240 patients 
from the inpatient units across both hospices. We estimate that 
80% of those recruited will complete the assessments, allowing 
data analysis on at least 200, slightly above the 176 needed.
Screening
Eligibility screening will take place every morning, and 
opportunistically, if practical, throughout the working day, as 
new patients are admitted to the hospice inpatient units. The clini-
cal care team will identify potentially eligible participants by 
considering a checklist with the inclusion and exclusion cri-
teria, as shown in Table 3. For patients screened as ineligible, 
age and reason for ineligibility will be recorded. If the reason 
for not approaching the patient later resolves (e.g. high level 
of patient and/or family distress or acute life-threatening ill-
ness requiring time-critical intervention), the patient may be 
approached on another occasion.
Table 2. Delirium diagnostic criteria of the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders 
(DSM-5)1.
A. A disturbance in attention (i.e. reduced ability to direct, focus, sustain, and shift attention) and awareness (reduced orientation 
to the environment).
B. The disturbance develops over a short period of time (usually hours to a few days), represents a change from baseline 
attention and awareness, and tends to fluctuate in severity during the course of a day.
C. An additional disturbance in cognition (e.g. memory deficit, disorientation, language, visuospatial ability, or perception).
D. The disturbances in Criteria A and C are not better explained by another pre-existing, established, or evolving neurocognitive 
disorder and do not occur in the context of a severely reduced level of arousal, such as coma
E. There is evidence from the history, physical examination, or laboratory findings that the disturbance is a direct physiological 
consequence of another medical condition, substance intoxication or withdrawal (i.e. due to a drug of abuse or to a medication), 
or exposure to a toxin, or is due to multiple etiologies.
Reprinted with permission from the Diagnostic and Statistical Manual of Mental Disorders, Fifth edition (Copyright 2013). American Psychiatric 
Association. All Rights Reserved.
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Figure 1. Study overview flow chart (adapted from Shenkin et al. (2008)39).
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Table 3. Inclusion and exclusion criteria.
Inclusion criteria
•   Aged 18 years or over 
•   Acutely admitted to the specialist palliative care inpatient units.
Exclusion criteria
•   Coma 
•    Unable to communicate in English (The cognitive tests used have not been validated in non-English language 
speakers, hence the study only includes patients who can communicate fluently in English).
•   Severe dysphasia 
•   Combined severe hearing and visual impairment, which would limit participation in the study’s tests. 
•   High level of patient and family distress, as judged by the clinical team. 
•   Acute life-threatening illness requiring time-critical intervention (e.g. suspected spinal cord compression)
Recruitment processes for participants with and 
without capacity
Eligible patients will be approached by the clinical team and 
asked if they would like to hear more about the study. If agree-
able, the clinical researcher will provide verbal and written 
information about the study and invite them to take part. As part 
of this discussion, the patient’s capacity to consent to partici-
pation in the study will be assessed. If the patient is assessed as 
lacking capacity to decide, their legal proxy will be approached. 
The legal proxy could be their Welfare Attorney, Guardian 
or nearest relative (this is the order in which they will be 
approached). They will be asked to consider the previously 
expressed views of the patient, and if they think the patient 
would have wanted to participate in the study. The Adults with 
Incapacity (Scotland) Act 2000 permits a legal proxy to consent 
on behalf of an adult with incapacity45.
Due to the nature of delirium, it is possible the partici-
pant’s capacity to consent may fluctuate. If participants with 
capacity continue with the assessments shortly after giving 
consent, they are unlikely to lose capacity within this short 
space of time. However, if there is a longer period between 
the capacity/consent process and assessments, it is possible 
that a participant’s capacity may be lost or regained in the 
intervening period. The researcher will need to ensure that 
the capacity and consent remain valid just prior to the assess-
ments being completed. That is, if a participant later regains 
their capacity after proxy agreement has been obtained, they 
will be given an opportunity to provide informed con-
sent for themselves. However, if the researcher becomes 
aware the previously competent participant has now lost 
capacity, the assessments will continue in view of their 
previous consent.
Participants are free to withdraw from the study at any time, 
or the researcher may withdraw a participant. The reason for 
their withdrawal will be documented, if available, and data 
collected up to that point, will be used.
Training of data collectors
The 4AT assessors are hospice inpatient nurses and doctors, 
who completed delirium training, either during preparation for 
the study and/or as part of their professional training. Prior 
to the study, the 4AT was routinely used on admission to the 
inpatient units, and at other times when delirium was suspected. 
The reference standard assessors are also part of the clini-
cal team. Prior to study recruitment, these assessors completed 
additional training in capacity assessment, obtaining consent 
and delirium assessment with a Post-Doctoral Research Fellow 
and psychologist (ZT) and the Chief Investigator (AMJM), to 
ensure competence. Good Clinical Practice was also completed.
Assessments
1. Index test
The 4AT takes a few minutes to complete and is described 
earlier in this protocol22.
2. Reference standard assessment
The reference standard assessment may take up to 20 minutes 
to complete and is based on the delirium diagnostic criteria 
in the fifth edition of the Diagnostic and Statistical Manual of 
Mental Disorders (DSM-5) (Table 2)1. The battery of tests 
assessing cognition and attention includes reverse days of the 
week, counting down from 20 to 1, Vigilance ‘A’49, the Obser-
vational Scale for Level of Arousal47, the modified Richmond 
Agitation Sedation Scale (the term ‘drowsy’ is used instead 
of ‘sedation’)48 and the Delirium Rating Scale-Revised-98 
(DRS R-98)26. A diagnosis of dementia or learning disability 
will be recorded. The assessor will review the patient’s clinical 
records and speak with someone who knows the patient 
well, such as a member of the clinical team and/or relatives 
(with the patient’s consent).
Following the reference standard assessment, the participant 
will be grouped into one of four categories – delirium present, 
possible delirium, no delirium, or undetermined, as defined in 
another recent delirium study49 (Table 4).
Where there is uncertainty of the patient’s categorisation, the 
reference standard assessor will discuss these ‘challenging 
cases’ with an expert panel. This panel includes a Consultant in 
Palliative Medicine (JS) and the Chief Investigator, who is a 
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Table 4. Reference standard assessment grouping (adapted from Rutter et al. (2018)49).
Category Criteria
Delirium present All 5 of the DSM-5 delirium core diagnostic criteria are positive
Possible delirium Some DSM-5 delirium diagnostic criteria are positive (i.e. some features of delirium are present), 
but not all, due to missing information (perhaps about the history of onset of symptoms).
No delirium present The core criteria are negative for delirium.
Undetermined Some, but not all, DSM-5 delirium criteria are positive. This usually represents a resolving or 
subsyndromal delirium.
Consultant in Medicine of the Elderly (AMJM). The panel will 
be blinded to the results of the 4AT, until the final categorisation 
of the reference standard assessment is complete.
Data collection
Each participant will complete the 4AT and a reference standard 
delirium assessment by two independent clinicians. The asses-
sor, who conducted the capacity and consenting process, will 
always administer the reference standard assessment. Given 
the fluctuating nature of delirium, the two assessments will be 
completed within a maximum three-hour time period (target 
interval 15 minutes). During this period, there will be no 
communication about the participant between the two asses-
sors, until both assessments are complete (other than to arrange 
the timing of assessments).
The order of the two assessments will be randomised in a 1:1 
ratio. The randomisation allocation will occur immediately 
following recruitment. An administrator at each site, who is 
independent of the assessments, will use a block randomised 
list to direct the order of the assessments.
Once both assessments are complete, the outcome of the 
reference standard assessment will be communicated verbally 
to the clinical team looking after the patient, in accordance with 
the consent process. This is because a provisional research 
diagnosis of delirium may result in improved patient care.
Data recording, storage and monitoring
Data will be recorded on paper case report forms and kept 
securely in locked cabinets, in offices with limited access. Study 
data collection forms (4AT and reference standard assessment 
results etc.) will be identified by a participant’s unique identi-
fication (ID) number only, to maintain confidentiality. Records 
with the participant’s name and other personal identifiers 
(eligibility and recruitment logs, consent forms etc.) will 
be stored separately from data collection forms with the 
participant’s ID only.
Clinical researchers will transcribe the data on case report 
forms into secure databases within Marie Curie Cancer Care IT 
networks in Edinburgh and Glasgow. The databases will only 
be accessible to clinical researchers and the Research steering 
committee, who will be responsible for monitoring the data 
quality.
Data analysis
The diagnostic test accuracy of the 4AT for delirium detection 
in specialist palliative care inpatient populations, versus the 
reference standard, will be determined using sensitivity, spe-
cificity, and positive and negative predictive values. The exact 
binomial 95% confidence interval will be reported for each 
measure. A ROC curve analysis will be performed, and the area 
under the ROC curve and its 95% confidence interval will be 
reported. Analyses will be completed using IBM SPSS Statistics.
Participants with missing data from the 4AT and reference stand-
ard assessments will be included in the statistical analysis, if 
there is enough information to decide on categorisation. Cases 
with insufficient information will be excluded, and expert panel 
advice will be sought where there is uncertainty.
Data protection
Data will be collected, stored and handled in accordance with 
guidance from Marie Curie Research Governance commit-
tee, the sponsor ACCORD (the Academic and Clinical Central 
Office for Research and Development) and the NHS Scotland 
A Research Ethics Committee.
The principle investigator will have direct access to their own 
site’s data, and to the other site’s on request. To ensure confiden-
tiality, the Research steering committee will only have access to 
data that has had identifiable participant information removed.
Personal data will be stored securely for a maximum of three 
years to allow full analysis of the data. Study documentation will 
not be destroyed without permission from the sponsor.
Study oversight
There is a process for reporting adverse events, however 
this is a relatively ‘low risk’ study - the assessors are trained 
palliative care nurses and doctors, and the study tests are 
already used in clinical practice. The sponsor, ACCORD, 
will be responsible for external oversight, which may involve 
monitoring and audit of study activity and documentation.
Study status
Recruitment commenced in October 2019. We initially antici-
pated that recruitment would run for up to 15 months, however 
recruitment was temporarily stopped in March 2020 due to the 
coronavirus disease 2019 (COVID-19) pandemic. Recruitment 
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will resume as soon as permitted, in line with research and 
clinical governance requirements.
Dissemination of information
The anonymised data will be shared on the ISRCTN Registry 
within 18 months of trial completion, and we hope to publish 
the results in an open access peer reviewed journal. The trial was 
registered retrospectively with ISRCTN on 21st February 2020 
(ISRCTN97417474).
Reporting guidelines
This protocol is reported in line with the SPIRIT guidelines50. 
A completed SPIRIT checklist for this protocol is available on 
the ISRCTN registry (ISRCTN97417474).
Discussion/implications
A recent survey of UK palliative care specialists reported the 
majority (68%) only screened for delirium when suspected clini-
cally, and few (5%) screened routinely on admission to palliative 
care units43. Only a third of respondents (37%) used assess-
ment tools to screen for delirium, despite international guidance 
advocating their use. Inadequate delirium training and guid-
ance, as well as the ‘complexity of patient’s conditions’ were 
perceived as barriers to delirium screening. The consequence 
of health care professionals not using assessment tools, is 
that delirium, particularly the hypoactive subtype, might go 
unrecognised and hence untreated in these patients.
The 4AT is a delirium assessment tool with strong evidence 
of validity in hospitalised patients. Whilst it is used in 
specialist palliative care settings, it has not been validated. If this 
study shows the 4AT to be an effective tool in this population, it 
may be more readily adopted into routine practice than other 
more complex and lengthy tools. If delirium is detected earlier, 
it may lead to better outcomes for these patients and their fami-
lies. The findings from this study will provide evidence for the 
use of the 4AT in hospice settings, and help inform clinical 
guidelines and practice in relation to delirium assessment 
in palliative care.
Declarations
Ethics approval and consent to participate
Approval was granted by NHS Scotland A Research Ethics 
Committee (REC reference 19/SS/0091 on 15th October 2019) 
and Marie Curie Research Governance committees. Participants 
will receive verbal and written information about the study, and 
sign a consent form, prior to assessments being conducted. If 
a participant lacks capacity to decide, signed consent will be 
sought from their legal proxy, as permitted by the Adults with 
Incapacity (Scotland) Act 2000.
Trial sponsor
The Academic and Clinical Central Office for Research and Devel-
opment (ACCORD), is a partnership between the University of 
Edinburgh and NHS Lothian Health Board. Address: Queen’s 
Medical Research Institute, 47 Little France Crescent, Edinburgh, 
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This is a well written study protocol for the validation of the 4AT tool for delirium detection in 2 
hospice inpatient units in Scotland. Recruitment for the study commenced in October 2019. The 
4AT is a brief 4-item bedside test and is the most commonly used delirium assessment tool in non-
intensive care settings in the UK1. While the 4AT takes a few minutes to complete and does not 
require special training prior to its use, the reference standard assessment (based on DSM-5 
delirium diagnostic criteria) used in this study may take up to 20 minutes to complete (as includes 
several tests assessing cognition and attention) and requires assessor training. 
 
Delirium is very common in palliative care patients and remains underdiagnosed, especially the 
hypoactive psychomotor subtype as palliative care patients commonly experience symptoms such 
as fatigue and depression. In addition, assessing delirium towards the end of life is often 
challenging as a patient’s condition declines. This study is warranted as further research is needed 
in evaluating tools for delirium screening/detection in different palliative care settings and 
populations2.  
 
The study aims to recruit 240 patient participants. I do not have sufficient statistical expertise to 
be able to comment on the suitability of this sample size. 
 
As this is a study protocol, my response to the peer review question regarding presentation of 
datasets is ‘not applicable’, but this was not an available option. 
 
Comments: 
The protocol states (in Data Analysis) that “participants with missing data from the 4AT and 
reference standard assessments will be included in the statistical analysis, if there is sufficient 
information to decide on categorisation.” The number of patients who are unable to complete 
particular tests of cognition and attention (done as part of the reference standard assessments) 
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may provide useful evidence with respect to the utility/ possible burden of these tools in this 
patient population. 
 
Similarly as this study is being conducted in hospice inpatients, it would be useful to record the 
Palliative Performance Status, or similar performance status tool, of the patient at the time of the 
4AT and reference standard assessments as performance status may predict a patient’s prognosis. 
I did not see performance status explicitly mentioned in the protocol. 
 
Inclusion and exclusion criteria:
Figure 1: 2nd box: Should it be “patient meets the inclusion or exclusion criteria”? 
 
○
Table 3: Check language used for inclusion criteria, as a specialist inpatient palliative care 
unit is usually in an acute care hospital. The term “inpatient hospice” is used in Abstract and 
Plain Language Summary, so perhaps hospice inpatient unit is a better term here?
○
Recruitment processes:
Given that trained reference standard assessors need to be available, is the study running 
seven days a week, or just Monday to Friday?
○
Training of data collectors:
For clarification within the text, are the 4AT assessors “Assessor B” and are the reference 
standard assessors “Assessor A” from Figure 1? 
 
○
Suggest specify how long the 4AT has been in routine use in the 2 hospices as this could 
impact on how the tool is used in each setting. Has the 4AT been used for a similar or 
different length of time in each hospice? 
 
○
Does “Good Clinical Practice” refer to the International Conference on Harmonisation-Good 
Clinical Practice (ICH-GCP) online training module?
○
Assessments:
The authors state that “the modified Richmond Agitation-Sedation Scale” would be used, so 
I had been anticipating the “Modified RASS” as developed by Chester et al.,3 but see that the 




If a patient is found to be “unassessable” for DSM-5 category ‘C’, will they also be 
categorised as “possible delirium” (Table 4)?
○
Additional minor points:








Consider adding the RASS to the list of abbreviations 
 
○
The MDAS is listed as the 1st tool in Table 1, but is not listed as a delirium tool in the last 
paragraph of Page 3. 
 
○
Table 1: There is another validation paper in cancer patients that has recently been ○
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published on the SQiD in BMC Cancer6.  
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The authors present the protocol of a validation study for the 4AT delirium screening tool for 
patients treated in specialist palliative care institutions. This tool will be compared to the clinical 
standard diagnostic procedure for delirium according to the Diagnostic and Statistical Manual of 
Mental Disorders (DSM 5). The protocol covers an important and highly debated topic, as delirium 
is common in palliative care and often underdiagnosed. The article is well written and the 
methods are clearly described. The estimation of the necessary sample size can not be verified by 
the reviewer, but the parameters chosen appear to reflect the well-known difficulty of achieving 
adequate sample sizes in palliative care. Inclusion and exclusion criteria are clearly stated. The 
authors report that assessors for the 4AT will receive training on delirium detection. It would be 
desirable to know a bit more about the intensity of this training, as the 4AT tool is supposed to be 
usable without training. Extensive training of staff on delirium detection could be a potential 
confounder. 
 
Just a minor suggestion: it would be helpful for the reader to have the details of the 4-A-Test 
readily available. The link to the website (ref. 22) is easily overread, perhaps a sentence about the 
website and the link could be a service. 
 
Monitoring and reporting recommendations are met and ethical approval is obtained. The 
consequences of the diagnosis of delirium for the patients are described so that patients receive 
adequate treatment. 
 
As the authors state, there are already some screening tools for delirium that are validated for use 
in palliative care settings, each with certain advantages and disadvantages (for a recent review see 
Watt et al.1). The 4AT already has proven usability in different areas and could be of value because 
of its brevity especially in palliative care. 
 
In summary, this is a well-designed study protocol that hopefully will help to improve screening 
for delirium in specialist palliative care services. 
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